Emerging Therapies in Relapsed or Refractory Multiple Myeloma - Episode 3

OCEAN Trial

Kenneth Shain, MD, PhD reviews phase 3 OCEAN study design and safety and efficacy data from patients with RRMM treated with melphalan flufenamide + dexamethasone doublet or pomalidomide + dexamethasone.